Lipid testing in 2020

9:00am CEST

June 4, 2020

Total cholesterol, triglycerides, HDL-cholesterol, and (measured or calculated) LDL-cholesterol constitute the traditional lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD), and all guidelines recommend using LDL-cholesterol as the primary target of lipid-lowering strategies to prevent ASCVD.

Despite the overwhelming evidence that LDL-targeted therapies effectively reduce ASCVD in the population, many individuals experience ASCVD or progression of atherosclerosis despite not having elevated LDL-cholesterol or even low concentrations <1.8 mmol/L (70 mg/dL). This residual risk indicates that a focus solely on the measurement of LDL-cholesterol is not an optimal strategy for all patients.

Therefore, increasing attention is being focused on the assessment of residual risk of ASCVD using additional risk markers – Remnant-cholesterol and Lp(a) – and comprehensive markers – calculated non-HDL-cholesterol and apoB – of atherogenic lipoproteins beyond LDL.

Accordingly, this webinar will focus on the strengths and weaknesses of emerging and traditional lipid tests and will provide guidance on which marker to preferably test in the contemporary and future settings of risk assessment and therapeutic targeting for the prevention of ASCVD.

Presenter
Michel R. Langlois MD, PhD
Professor
Ghent University
View Biography
Presenter
Moderator: Anthony Newman
Senior Publisher
Elsevier, The Netherlands – publisher of the Clinica Chimica Acta

Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Submit